appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Eris Lifesciences Ltd
ERIS
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Zydus Lifesciences Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Eris Lifesciences Q1 Results Review - Inline; Strong Start To Business Integration: Prabhudas Lilladher
1 month ago•Bloomberg Quint
Eris Lifesciences net profit drops 4.5% to Rs 89 crore in Q1FY25
1 month ago•Economic Times
Eris Lifesciences Q1 Results: Net dips 4.5% YoY at Rs 89 crore
1 month ago•Economic Times
ERIS Lifesciences consolidated net profit declines 12.31% in the June 2024 quarter
1 month ago•Business Standard
2 top stock recommendations from Aditya Arora
1 month ago•Economic Times
Recent EventsAll events
Notice Of Shareholders Meetings-XBRL
Eris Lifesciences Limited has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 25-Sep-2024 | Download
Eris Lifesciences Limited has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 25-Sep-2024 | Download
Cash Dividend
Interim • Div/Share: ₹ 7.35
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant